Ciaramella Giuseppe 4

What Happened

• Giuseppe Ciaramella, President of Beam Therapeutics (BEAM), exercised 35,000 stock options with an exercise price of $17.00 (cost $595,000) on February 24, 2026, and the resulting 35,000 shares were sold the same day for a weighted average price of $32.00, generating proceeds of approximately $1,120,042. The Form 4 also reports the derivative (the exercised option) as disposed (no cash proceeds recorded for the derivative instrument).

Key Details

• Transaction date: February 24, 2026; Form 4 filed February 26, 2026 (filed within the standard two-business-day window).
• Exercise: 35,000 shares @ $17.00 = $595,000 (code M — option exercise).
• Sale: 35,000 shares @ weighted avg $32.00 = $1,120,042 (code S — open market sale). Sales occurred at prices ranging $32.00–$32.04 (weighted average reported).
• Derivative disposition: 35,000 @ $0.00 reported as disposed (reflects the exercised option instrument).
• Footnotes: F1 — sale executed pursuant to a Rule 10b5-1 trading plan adopted Sept 30, 2025; F2 — sale price is a weighted average across multiple trades ($32.00–$32.04); F3 — option vesting schedule (25% at first anniversary from Feb 5, 2020, then monthly thereafter).
• Shares owned after transaction: not specified in the provided excerpt — see the full Form 4 for post-transaction holdings.

Context

• This is a routine cashless exercise + immediate sale: the insider exercised vested options and sold the resulting shares under a pre-established 10b5-1 plan. Such transactions convert option holdings into cash and do not, by themselves, indicate the insider’s private view of the company’s long-term prospects.
• The option vesting footnote indicates the option follows a standard multi-year vesting schedule (started Feb 5, 2020), so the exercised options were from that granted pool.